Opportunistic Infections
ACTHIV
Denver, 2011

Daniel Skiest, M.D.
Chief, Infectious Diseases,
Baystate Medical Center
Professor, Tufts University School of Medicine

Learning Objectives

Upon completion of this presentation, learners should be better able to:

- Identify important opportunistic infections affecting HIV+ individuals in the HAART era
- Diagnose and manage immune reconstitution syndrome

Design: A prospective cohort study of 8070 participants in the HIV Outpatient Study at 12 U.S. HIV clinics.

Buchacz et al *AIDS* 2010, **24**:1549–1559



Fig. 1. Incidence of AIDS-defining opportunistic illnesses, the HIV Outpatient Study, 1994–2007. (a) High-frequency opportunistic infections; (b) opportunistic malignancies.

Hospitalization for OIs decreasing: U.S.

TABLE 2. Number of HIV Hospitalizations Stratified by Diagnosis and Year

Diagnosis Category	1996	1998	2000
Opportunistic illnesses	51,050 (40%)	28,242 (29%)	24,661 (27%)
Liver-related complications	10,481 (8%)	9801 (10%)	11,583 (13%)
Chronic HCV	1495 (1%)	2607 (3%)	4690 (5%)
Pneumonia	13,230 (10%)	11,875 (12%)	12,461 (14%)
IDU-related complications	6390 (5%)	5560 (6%)	5238 (6%)
Diabetes	4073 (3%)	4011 (4%)	4591 (5%)
Ischemic heart disease	462 (0.4%)	586 (0.6%)	799 (0.9%)
Cerebrovascular disease complications	641 (0.5%)	524 (0.5%)	605 (0.7%)

Diagnosis categories were not mutually exclusive. Entries are number of hospitalizations, with percentage of HIV-related hospitalizations for that diagnostic category in each year in parentheses.

Gebo, K et al. JAIDS 2005; 40, 609

Reasons for hospitalization: HAART era

1. Non-AIDS related illness
   - Substance abuse
   - Medication adverse event
   - Other
     - MI, CVA etc
     - infection
     - elective surgery
     - DM

2. AIDS related illness
   - Opportunistic Infection
     - Classic OI
     - Other “OI”- hepatitis C
     - IRIS
   - Malignancy
     - HIV related
     - HIV non-related

OIs- Diagnosis

Data needed to make diagnosis

- Recent CD4
- Nadir CD4
- Prior History including OIs, etc
- Geography/travel

- Generally not required
  - HIV viral load
  - CD4 count during hospitalization

High incidence bacterial pneumonia: Veterans Aging Cohort



Figure 1. (*A* and *B*) Unadjusted incidence per 1,000 person-years of pulmonary disease by HIV status. Incidence rates of each pulmonary condition are shown per 1,000 person-years on the *y* axis. Rates for HIV-infected patients (HIV+) are shown in the *solid bars*, and for HIV-uninfected patients (HIV−) are shown in the *shaded bars*. *$P < 0.05$ for HIV+ compared with HIV− patients. COPD = chronic obstructive pulmonary disease; PCP = *Pneumocystis* pneumonia; TB = tuberculosis.

Crothers et al A J Resp Cr Care Med 2011

Bacterial Pneumonia

- Community Acquired Pneumonia common
- Invasive Pneumococcal disease incidence 50x in HIV
- Risk factors
  - Smoking, low CD4, IDU, alcohol abuse, malnutrition, no HAART , ART interruption
- Symptoms:
  - Typical: cough, fever, chills, dyspnea +/- pleuritic chest pain
- Treatment- same as non-HIV
  - Outpatient: Macrolide Or doxycycline
  - Inpatient: respiratory quinolone OR 3rd gen ceph + macrolide

- *immunize for pneumococcus and influenza

Mandell et al. IDSA CAP Guidelines CID 2007;44, S2772

Case

43 y.o. female with AIDS:

nonproductive cough, feverishness, and chills. dyspnea on exertion, anorexia, myalgias, and generalized weakness.

Current Meds: raltegravir, Epzicom for 6 mos

Adherence?

PMH

- AIDS since 1996, CD4 count nadir 14, MTb (Rx), PCP

PE: T 101.9, pulse 144, RR 22, BP 129/87, oxygen sat. 92% on RA

Exam : thrush, no rales, or wheezes

LABS:

7.46/32.6 /70 /23./95%

- LDH 393 AST 65 ALT 31 Bili 0.3
- WBC 3.1 HCT 40.2
- CD4 1 mo. ago 42, HIV VL 26,000 cps/mL


[H] CHEST 2 VIEWS FRONTAL AND...
04-Feb-2010 10:20:12
07-Oct-1966
female
[R]
5 cm [*]
acq kvp: 90.0kV
1494x1750
W/L: 3400/4191
lossy compressed, ratio 1 : 11
DX
Img 1

What is most likely diagnosis?

Diagnosis?

1. bacterial pneumonia
2. Acute bronchitis
3. Tuberculosis
4. PJP
5. CMV pneumonitis

Diagnosis?

1. bacterial pneumonia
2. Acute bronchitis
3. Tuberculosis
4. **PJP**
5. CMV pneumonitis

PCP

- Fungus- *P. jirovecii*
- CD4 < 200
- NP cough, fever, dyspnea, NS, wt loss (days to weeks)
- Exam- normal or fine basilar rales
- Labs- hypoxemia, high LDH
- CXR- bilateral, symmetric interstitial infiltrates (can be nl)
- HR CT- more sensitive
- Diagnosis:
  - CXR, LDH
  - Induced sputum for DFA ~50% sensitive
  - BAL- sensitivity 90% (gold std)
  - Exercise- oxygen desaturation



dpd.cdc.gov/.../Pneumocystis_IFA_B.jpg

PCP DFA BAL



Pneumocystis jiroveci cysts in BAL; silver stain

With permission Edward Lulo

PCP Therapy

Severe:

- Trimethoprim-sulfamethoxazole: 15mg/kg/d TMP- 21 days
- Toxicities: rash, fever, nephrotoxicity, bone marrow suppression
- Pentamidine 3mg/kg/day - 21 days
- Toxicities: nephrotoxicity, hypo and hyperglycemia and pancreatitis

Mild to moderate:

- TMP/SMX
- clindamycin/primaquine - Hemolytic anemia, check G6PD
- atovaquone
- trimethoprim/dapsone

Include corticosteroids if $pO_2 < 70$ or A-a gradient > 35

Walzer P et al. in Mandell, Douglas, Bennett's Principles Practices Inf. Dis 2010

Tuberculosis



- 1/3 Primary Tb, 2/3's reactivation (100 fold higher risk in HIV)
- Extrapulmonary Tb common (50%)
- Chest x-rays may lack classic upper lobe cavitary lesions -(esp CD4 < 50).
- PPD (or IFN-γ release assay) often falsely – (anergy)
- Dx: AFB smear 50% sensitivity, PCR 80%
  - culture gold std (weeks)
- **Treatment** (DOT): INH/rif/PZA/ethamb 2 mos, then INH/rif for 4 mos
  - Latent infection: INH (9 mos)
- Initiation of HAART (early preferred)

Fitzgerald et al. in Mandell, Douglas, Bennett's Principles Practices Inf. Dis 2010

PCP vs Bacterial pneumonia vs Tb

Table 5. Multiple regression model of predictors of diagnosis of bacterial pneumonia, *Pneumocystis carinii* pneumonia, and pulmonary tuberculosis.

Variable	OR (95% CI)	*P*
Likelihood of a diagnosis of *P. carinii* pneumonia (n = 99; log likelihood = –90.71)		
Interstitial infiltrate	10.18 (4.71–21.97)	< 0.001
Exertional dyspnea	4.91 (2.20–10.95)	< 0.001
Oral thrush on admission	2.85 (1.35–6.02)	0.01
Percentage granulocytes >75%	2.73 (1.24–6.00)	0.01
Clear sputum	2.12 (0.96–4.88)	0.08
Cough > 7 days	1.91 (0.88–4.15)	0.10
History of injecting drug use	0.19 (0.09–0.41)	< 0.001
Likelihood of a discharge diagnosis of bacterial pneumonia (n = 94; log likelihood = –88.15)		
Rhonchi	12.35 (3.99–38.28)	< 0.001
Toxic appearance	9.09 (1.85–44.70)	0.01
Fever ≤ 7 days	6.55 (2.50–17.19)	< 0.001
Lobar infiltrate	5.83 (2.11–16.11)	< 0.001
Pleuritic chest pain	2.99 (1.36–6.58)	0.01
Purulent sputum	2.46 (1.12–5.40)	0.03
Heart rate > 104 beats/min	2.16 (0.99–4.74)	0.05
History of injecting drug use	3.05 (1.39–6.70)	0.01
Likelihood of a diagnosis of pulmonary tuberculosis (n = 36; log likelihood = –78.82)		
Cavitary infiltrate	21.06 (3.81–116.42)	< 0.001
Fever > 7 days	3.86 (1.68–8.93)	< 0.001
Weight loss	3.63 (1.56–8.41)	< 0.001
History of injecting drug use	2.22 (0.97–5.14)	0.06

Selwyn et al AIDS 1998, 12:885

PCP vs BP vs Tb



Fig. 1. 25th, 50th, and 75th percentile values of room-air arterial oxygen pressure (pO_2; mmHg) and serum lactate dehyrogenase (LDH; U/l) on admission for HIV-infected patients with bacterial pneumonia (BP), tuberculosis (TB) or *Pneumocystis carinii* pneumonia (PCP).

Selwyn et al AIDS 1998, 12:885

Case

- 28 y.o. man with AIDS, CD4 42, not on HAART
- Presents with two weeks of headache, low grade fever
- Meds- Bactrim DS QD

Exam:

T 101.4, P 100, BP 120/87

- Slightly confused
- Neck- supple
- Fundi- normal
- Neuro -non focal

Next step?

1. Levaquin 500 mg for 5 days
2. CXR
3. Blood culture
4. LP
5. CT then LP
6. Start antiretrovirals

- CT normal
- LP performed
  - 4 WBCs, 2 RBC, protein 60, glucose 65
  - Gram stain negative

Other tests to send?

Send Cryptococcal antigen, fungal culture

Source- P. Southern

Cryptococcus

- *C. neoformans*
- CD4 < 100
- Sx: headache, fever, confusion
  -meningeal signs uncommon
- Diagnosis: Lumbar puncture
  cryptococcal antigen, culture
- Measure opening pressure!
- Utility of Serum CRAG

Cryptococcus: Treatment

- **Induction:** amphotericin B (0.7mg/kg/day) ± Flucytosine 100-150 mg/kg/d for 2 weeks

- **Consolidation:** po fluconazole 400mg/d for 8 weeks

- **Maintenance:** po fluconazole 200 mg/d until significant immune reconstitution

Source- P. Southern

Perfect at al. Clin Infect Dis 2010; 50:91

Case

- 30 y.o. BM presents with neck mass in 9-03

9-03

- 30 y.o. BM diagnosed with cryptococcal meningitis
- Initial CD4 = 4/0.7%, VL = 52,047
- CSF CRAG = 1:8192
- Rx: Liposomal Amphotericin for 15d the po fluconazole
- ART initiated 1 yr later : ABC, 3TC, Nelfinavir

Skiest et al J Infect 2005



From D. Skiest- unpublished

Date	2-02	1-03	4-03	8-03
CD4	4/7%	42	97/3%	231/5%

Diagnosis?

1. MAI
2. MTB
3. C. neoformans resistant to fluconazole
4. Immune reconstitution syndrome
5. NHL

Immune Recovery Inflammatory Syndromes (IRIS, IRS)

Immune Reconstitution Syndrome Definitions

- Atypical presentation of OI or tumor in response to ART

exaggerated/inflammatory and atypical reaction:

  - low initial $CD4^+$ cell count (<100c/μl)
  - rapid rise in $CD4^+$ T cells
  - Rapid decrease in VL (> 1 log)
  - High antigen burden
  - Exclude alternative diagnosis, drug reaction, Rx failure

- Timing variable- most 4-8 wks, range days to yrs

IRIS subtypes

- Paradoxical IRIS- worsening of treated OI (inactive infection)
- Unmasking IRIS- subclinical, untreated infections

IRIS Risk higher with low CD4



Figure 3: **Incidence of immune reconstitution inflammatory syndrome (IRIS) according to CD4 cell count at the start of antiretroviral therapy**
Data are provided for 22 studies. Circle size is proportional to weighting in the random-effect model.

CD4 at start of ART
- median 57
  (IQR 33-106)

Muller. Lancet ID 2010

IRIS common presentations

Mycobacteria

- MTB – Lymphadenopathy, ARDS, CNS, extra-pulmonary
- MAC / “MOTT” - Focal lymphadenitis, endobronchial

Fungal

- Cryptococcal Disease – Lymphadenopathy, meningitis, cryptococomma, pulmonary
- Histoplasmosis – mesenteric lymphadenopathy, fever
- Pneumocystis jirovecii – ARDS; granulomatous pneumonia

Viral

- CMV immune recovery vitritis,
- VZV

Drechsler H, et al. Clin Infec Dis 2004;38:1159-66; French MA, et al. AIDS 1992;6:1293-97.

IRIS Management

- Continue HAART if possible, to maintain immune recovery
- Institute/continue specific therapy for the pathogen (if available)
- Consider steroids: *esp CNS IRIS*
- Rarely hold HAART (if life-threatening)
- Treatment *prior* to HAART of recognized opportunistic infections

Drechsler H, et al. Clin Infec Dis 2004;38:1159-66

When to start HAART in acute OI?

Risk of IRIS

Risk of HIV progression



Earlier ART

- Improve immune function
- Prevent further OIs
- Improve outcome of acute OI
- IRIS?

Delayed ART

- Pt not ready
- Drug interactions
- Side effects- confusion re: Drug vs OI

HAART Timing in Acute OI

- For opportunistic conditions without effective therapy (e.g., cryptosporidiosis, microsporidiosis, PML) benefits of ART outweigh risks: begin HAART ASAP.
- In setting of opportunistic infections, (cryptococcus or non-tuberculous mycobacterial infections), for which immediate therapy may increase IRIS risk, consider short delay before initiating ART.
- For other opportunistic infections, such as *Pneumocystis jiroveci* pneumonia (PCP), early ART associated with increased survival: therapy should not be delayed.
- For active tuberculosis, initiate ART within the first 1−2 months of treatment for tuberculosis

CDC, MMWR 2009;58(RR-4): OI Guidelines - April 10, 2009

Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial



Figure 1. Study Subject Enrollment and Discontinuation.



Figure 3. Time to AIDS progression or death. HR=0.53 Early versus Deferred ART [95%CI 0.30–0.92 p=0.023].
doi:10.1371/journal.pone.0005575.g003

Zolopa et al. PLos one 2009; 4(5):e5575



Zolopa et al. PLos one 2009; 4(5):e5575

Figure 4. AIDS Progression/Death by entry diagnoses given as log Odds ratios (with 95%CI) with OR < 1.0 favoring early versus deferred ART. Total, fungal and CD4<50 categories represent significance at p<0.05. (Fungal Infections include cryptococcal infections and histoplasmosis).

Original Article

Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy

Salim S. Abdool Karim, M.B., Ch.B., Ph.D., Kogieleum Naidoo, M.B., Ch.B., Anneke Grobler, M.Sc., Nesri Padayatchi, M.B., Ch.B., Cheryl Baxter, M.Sc., Andrew Gray, M.Sc. (Pharm.), Tanuja Gengiah, M.Clin.Pharm., M.S. (Epi.), Gonasagrie Nair, M.B., Ch.B., Sheila Bamber, M.B., Ch.B., Aarthi Singh, M.B., Ch.B., Munira Khan, M.B., Ch.B., Jacqueline Pienaar, M.Sc., Wafaa El-Sadr, M.D., M.P.H., Gerald Friedland, M.D., and Quarraisha Abdool Karim, Ph.D.

N Engl J Med
Volume 362(8):697-706
February 25, 2010

The NEW ENGLAND JOURNAL of MEDICINE

Tb: SAPIT Trial

- 3 arm open label RCT, n = 642
- Tb smear +, CD4 < 500, on Tb RX
- 1° Endpoint
  - all cause mortality & new ADC
    - Integrated arms 55% reduction mortality

Kaplan-Meier Survival Curves



Abdool Karim SS et al. N Engl J Med 2010;362:697-706

The NEW ENGLAND JOURNAL of MEDICINE

Tb: SAPIT Trial

- Integrated arms

	Early	Late
Death	15	15
Events/ 100 person-yrs	6.9	7.8
CD4 < 50	68% decrease ADC/death	
CD4 < 50 CD4 ≥ 50	IRIS 5 fold increase 2 fold increase	

Abdool Karim, CROI 2011

Tb and HAART: DHHS panel

- All HIV+ patients with active TB start TB treatment immediately
- CD4 count <200 cells/mm3, ART should be initiated within 2–4 weeks of starting TB treatment
- CD4 count 200–500 cells/mm3, initiation of ART within 2–4 weeks, or at least by 8 weeks after start of TB therapy.
- For CD4 count >500 cells/mm3, most recommend starting ART within 8 weeks of TB therapy.

- Recent Data*
  - Consider starting HAART early (2 wks) if CD4 < 50
  - If CD4 > 50 consider waiting < 2 mos

- *STRIDE Study A5221, Havlir et al. CROI 2011 and SAPIT Study, Abdool Karim, CROI 2011

Criteria for stopping OI prophylaxis

OI	*1° prophylaxis*	*2° prophylaxis*
PCP	CD4 > 200 for 3M	CD4 > 200 for 3M.
MAC	CD4 > 100 for 3M	CD4 > 100 for 6M & completed 12M
Toxoplasma	CD4 > 200 for 3M	Completed Rx & CD4 > 200 for 6M
CMV	NA	Sustained CD4 >100 for 3-6M
Cryptococcus	NA	Completed Rx & CD4 > 200 for 6M
Histoplasmosis	CD4 > 150 for 6M (select circumstances)	CD4 > 150, ART 6M & completed Rx 12M
Coccidoides	NA	Lifelong (except focal pneumonia)

CDC, MMWR 2009;58(RR-4): OIs Guidelines - April 10, 2009

Opportunistic Infections

- Incidence declining
- Diagnosis: Recent CD4, nadir CD4
  - Prophylaxis
- IRIS
- Prevention: Early HAART